New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 13, 2014
12:01 EDTBTU, GILDStocks with call strike movement; BTU GILD
Peabody (BTU) September 22 call option implied volatility increased 4% to 34, Gilead (GILD) August 90 option implied volatility decreased 2% to 30 according to IVolatility.
News For BTU;GILD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
September 25, 2014
08:27 EDTGILDGilead viral suppression data for TAF better than expected, says UBS
UBS said the viral suppression data reported by Gilead from two studies of tenofovir alafenamide, or TAF, in HIV-1 treatment was better than expected and the firm expects the results to have a positive impact on adoption. The firm maintains its Buy rating and $125 price target on Gilead.
September 24, 2014
09:34 EDTGILDActive equity options trading on open
Subscribe for More Information
09:28 EDTGILDGilead price target raised to $118 from $111 at Piper Jaffray
Subscribe for More Information
08:39 EDTGILDGilead's two TAF Phase 3 trials meet primary objectives
Subscribe for More Information
05:12 EDTGILDGilead submits NDA to Japan for fixed-dose combination of Ledipasvir/Sofosbuvir
Gilead Sciences announced that the company has submitted a New Drug Application, or NDA, to Japanís Pharmaceutical and Medical Devices Agency, or PMDA, for approval of an investigational once-daily fixed-dose combination of the NS5A inhibitor ledipasvir, or LDV, 90 mg and the nucleotide analog polymerase inhibitor sofosbuvir, or SOF, 400 mg for the treatment of chronic genotype 1 hepatitis C virus, or HCV, infection in adults. The data submitted in the NDA, which include a Japanese Phase 3 study showing 100 percent SVR12 rates, support the use of LDV/SOF for 12 weeks in treatment-naÔve and treatment-experienced patients with chronic genotype 1 HCV infection, including those with cirrhosis. Patients who achieve SVR12 are cured of HCV infection. If approved, LDV/SOF would simplify HCV treatment for genotype 1 patients in Japan to one daily tablet, eliminating the need for interferon and ribavirin, or RBV. LDV/SOF is currently under regulatory review in the United States and European Union.
September 23, 2014
09:54 EDTBTUPeabody cuts Q3 adjusted EPS view to (69c)-(63c) from (49c)-(36c)
Consensus is (40c). Updated guidance primarily reflects the effects of non-cash tax expense following the repeal of the Minerals Resource Rent Tax in Australia. Peabody now sees Q3 adjusted EBITDA $190M-$210M vs. previous $150M-$200M view. "Peabody is pleased that strong cost improvements and operating results are leading to increased Adjusted EBITDA expectations even in the face of market challenges," said Peabody Energy Chairman and CEO Gregory H. Boyce. "Our operations are performing well as we experienced higher-than-expected results from the Western United States, improved performance from Australian metallurgical coal mines and continued cost reductions across the platform."
08:07 EDTGILDFDA Pediatric Advisory Committee to hold a meeting
Subscribe for More Information
September 22, 2014
09:15 EDTGILDIntercept recent weakness a buying opportunity, says Summer Street
Subscribe for More Information
September 19, 2014
11:26 EDTGILDStocks with call strike movement; TSLA GILD
Subscribe for More Information
09:37 EDTGILDActive equity options trading on open
Subscribe for More Information
06:25 EDTGILDGilead granted marketing aurhotization from European Commission for Zydelig
Subscribe for More Information
06:11 EDTGILDGilead price target raised to $139 from $111 at Citigroup
Citigroup raised its price target for Gilead shares to $139 saying management looks "very optimistic" that FY15 hepatitis C treatment volumes could be up substantially over FY14 rates globally. Citi also expects recent buybacks to boost Q4 earnings substantially and that future stock buybacks will drive appreciation. The firm keeps a Buy rating on Gilead.
September 18, 2014
14:46 EDTBTUPeabody sees Q3 Powder River Basin shipments above Q2 levels
Subscribe for More Information
14:45 EDTBTUPeabody says India thermal coal imports rising faster than expected
Subscribe for More Information
14:43 EDTBTUPeabody sees new China coal quality policies to have no negative impact
Subscribe for More Information
14:21 EDTBTUPeabody Energy volatility flat as shares trend to ten-year low
Peabody Energy September weekly call option implied volatility is at 31, October is at 33, December is at 31; compared to its 26-week average of 32 according to Track Data, suggesting non-directional price movement.
12:12 EDTGILDStocks with call strike movement; PIR GILD
Subscribe for More Information
10:00 EDTBTUOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
08:17 EDTGILDGilead trial failure not material, says FBR Capital
Subscribe for More Information
06:08 EDTBTUPeabody downgraded to Sell from Neutral at Goldman
Goldman downgraded Peabody to Sell based on a reduced met coal price forecast, valuation, low Australia margins, and high leverage levels. Price target lowered to $13 from $15.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use